Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alnylam
Pharma
BridgeBio’s Attruby cruises toward blockbuster land
As Alnylam’s Amvuttra sales disappointed, revenue from BridgeBio’s rival ATTR drug Attruby came above analysts’ expectations.
Angus Liu
Aug 11, 2026 11:22am
Alnylam shares tank 29% as Amvuttra disappoints
Jul 30, 2026 11:35am
AstraZeneca, Ionis shares slide with ATTR-CM trial failure
Jul 9, 2026 11:36am
Alnylam scolded over promotional activity after Pfizer complaint
Jun 22, 2026 9:46am
FDA signs off on pediatric use of Pfizer's hemophilia treatment
Jun 8, 2026 10:32am
Alnylam rebuked by FDA over efficacy claims on Amvuttra website
May 7, 2026 5:18am
